リコンビナントタンパク質＿精製したリコンビナントタンパク質 » リコンビナント成長因子 » FGF-basic, Human (154aa)
FGF-basic (154aa), Human

2 μg of FGF-basic, Human (Cat. No. Z03116) was resolved with SDS-PAGE under reducing (R) and non-reducing (N) conditions and visualized by Coomassie Blue staining.

FGF-basic (154aa), Human

2 μg of FGF-basic, Human (Cat. No. Z03116) was resolved with SDS-PAGE under reducing (R) and non-reducing (N) conditions and visualized by Coomassie Blue staining.

FGF-basic (154aa), Human

Measured by a cell proliferation assay using BALB/c 3T3 cells. The ED50 for this effect is < 0.25 ng/ml.

FGF-basic (154aa), Human

Fibroblast Growth Factor-basic (FGF-basic), also known as FGF-2, is a pleiotropic cytokine and one of the prototypic members of the heparin-binding FGF family. Like other FGF family members, bFGF has the β trefoil structure. In vivo, bFGF is produced by a variety of cells, including cardiomycotes, fibroblasts, and vascular cells. bFGF regulates a variety of processes including cell proliferation, differentiation, survival, adhesion, motility, apoptosis, limb formation and wound healing. bFGF can be tumorigenic due to its role in angiogenesis and blood vessel remodeling. The angiogenic effects of bFGF can produce beneficial cardioprotection during acute heart injury.
Z03116
¥9,327.00

Ask us a question
Product Introduction
Species Human
Protein Construction
FGF-basic (Ala135-Ser288)
Accession # P09038
Purity > 95% as analyzed by SDS-PAGE
Endotoxin Level < 0.2 EU/μg of protein by gel clotting method
Biological Activity ED50 < 0.25 ng/ml, measured by the cell proliferation assay using 3T3 cells, corresponding to a specific activity of > 4.0 × 106 U/mg.
Expression System E. coli
Apparent Molecular Weight ~17.1 kDa, on SDS-PAGE under reducing conditions.
Formulation Lyophilized after extensive dialysis against PBS.
Reconstitution It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH₂O up to 100 μg/ml.
Storage & Stability Upon receiving, this product remains stable for 6 months at lower than -70°C. Upon reconstitution, the product should be stable for 1 week at 4°C or for 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles.

Examples
  • FGF-basic (154aa), Human
    • FGF-basic (154aa), Human

    2 μg of FGF-basic, Human (Cat. No. Z03116) was resolved with SDS-PAGE under reducing (R) and non-reducing (N) conditions and visualized by Coomassie Blue staining.

  • FGF-basic (154aa), Human
    • FGF-basic (154aa), Human

    2 μg of FGF-basic, Human (Cat. No. Z03116) was resolved with SDS-PAGE under reducing (R) and non-reducing (N) conditions and visualized by Coomassie Blue staining.

  • FGF-basic (154aa), Human
    • FGF-basic (154aa), Human

    Measured by a cell proliferation assay using BALB/c 3T3 cells. The ED50 for this effect is < 0.25 ng/ml.


Background
Target Background Fibroblast Growth Factor-basic (FGF-basic), also known as FGF-2, is a pleiotropic cytokine and one of the prototypic members of the heparin-binding FGF family. Like other FGF family members, bFGF has the β trefoil structure. In vivo, bFGF is produced by a variety of cells, including cardiomycotes, fibroblasts, and vascular cells. bFGF regulates a variety of processes including cell proliferation, differentiation, survival, adhesion, motility, apoptosis, limb formation and wound healing. bFGF can be tumorigenic due to its role in angiogenesis and blood vessel remodeling. The angiogenic effects of bFGF can produce beneficial cardioprotection during acute heart injury.
Synonyms Fibroblast Growth Factor-basic; FGF-2; BFGF; FGFB; HBGF-2; bFGF; Prostatropin

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.